Characteristic Adverse Events and Their Incidence Among Patients Participating in Acute Ischemic Stroke Trials

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Stroke

• Publication date

  2014-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/STROKEAHA.114.005845PMID 25082807
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development, Expansion, and Use of a Stroke Clinical Trials Resource for Novel Exploratory Analyses

  2012cited by this paper
• Development, expansion, and use of a stroke clinical trials resource for novel exploratory analyses.

  2012cited by this paper
• Birth Size Distribution in 3,705 Infants Born to Mothers With Type 1 Diabetes

  2011cited by this paper
• Phase IIB/III Trial of Tenecteplase in Acute Ischemic Stroke: Results of a Prematurely Terminated Randomized Clinical Trial

  2010cited by this paper
• Effect of Combined Aspirin and Extended-Release Dipyridamole Versus Clopidogrel on Functional Outcome and Recurrence in Acute, Mild Ischemic Stroke: PRoFESS Subgroup Analysis

  2010cited by this paper
• AXIS: A Trial of Intravenous Granulocyte Colony-Stimulating Factor in Acute Ischemic Stroke

  2010cited by this paper
• Randomized, Placebo-Controlled, Dose-Ranging Clinical Trial of Intravenous Microplasmin in Patients With Acute Ischemic Stroke

  2009cited by this paper
• Primary End-Point Times, Functional Outcome and Adverse Event Profile after Acute Ischaemic Stroke

  2009influential reference
• Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke

  2009cited by this paper
• Stroke Outcome in Clinical Trial Patients Deriving From Different Countries

  2009cited by this paper
• Ancrod in Acute Ischemic Stroke: Results of 500 Subjects Beginning Treatment Within 6 Hours of Stroke Onset in the Ancrod Stroke Program

  2009cited by this paper
• Effect of Telmisartan on Functional Outcome, Recurrence, and Blood Pressure in Patients With Acute Mild Ischemic Stroke: A PRoFESS Subgroup Analysis

  2009cited by this paper
• A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients With Acute Ischemic Stroke: Modified Randomized Exposure Controlled Trial (mRECT)

  2009cited by this paper
• The Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke: The CLEAR Stroke Trial

  2008cited by this paper
• NXY-059 for the Treatment of Acute Stroke: Pooled Analysis of the SAINT I and II Trials

  2008cited by this paper
• Allopurinol Use Yields Potentially Beneficial Effects on Inflammatory Indices in Those With Recent Ischemic Stroke: A Randomized, Double-Blind, Placebo-Controlled Trial

  2008cited by this paper
• Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke: Results of an International Phase III Trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II)

  2008cited by this paper
• Does Hemispheric Lateralization Influence Functional and Cardiovascular Outcomes After Stroke?: An Analysis of Placebo-Treated Patients From Prospective Acute Stroke Trials

  2008cited by this paper
• DP-b99, a Membrane-Activated Metal Ion Chelator, as Neuroprotective Therapy in Ischemic Stroke

  2008cited by this paper
• UvA-DARE ( Digital Academic Repository ) Calcium antagonists in stroke

  2007cited by this paper
• NXY-059 for the treatment of acute ischemic stroke.

  2007cited by this paper
• Prophylaxis of Thrombotic and Embolic Events in Acute Ischemic Stroke With the Low-Molecular-Weight Heparin Certoparin: Results of the PROTECT Trial

  2006cited by this paper
• NXY-059 for acute ischemic stroke.

  2006cited by this paper
• Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke: Results of a Randomized Phase 2 Trial

  2005cited by this paper
• Pneumonia and urinary tract infection after acute ischaemic stroke: a tertiary analysis of the GAIN International trial

  2004influential reference
• Argatroban Anticoagulation in Patients With Acute Ischemic Stroke (ARGIS-1): A Randomized, Placebo-Controlled Safety Study

  2004cited by this paper
• Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): An Adaptive Dose-Response Study of UK-279,276 in Acute Ischemic Stroke

  2003cited by this paper
• Cause-Specific Mortality After First Cerebral Infarction: A Population-Based Study

  2003cited by this paper
• AMPA Antagonist ZK200775 in Patients With Acute Ischemic Stroke: Possible Glial Cell Toxicity Detected by Monitoring of S-100B Serum Levels

  2002cited by this paper
• ATLANTIS Trial: Results for Patients Treated Within 3 Hours of Stroke Onset

  2002cited by this paper
• The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator–treated stroke (CLASS-T)

  2001cited by this paper
• A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients

  2001cited by this paper
• Tolerability of the Low-Affinity, Use-Dependent NMDA Antagonist AR-R15896AR in Stroke Patients: A Dose-Ranging Study

  2001cited by this paper
• Incidence of and Risk Factors for Medical Complications During Stroke Rehabilitation

  2001influential reference
• Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial.

  2001cited by this paper
• Effect of Paracetamol (Acetaminophen) on Body Temperature in Acute Ischemic Stroke: A Double-Blind, Randomized Phase II Clinical Trial

  2001cited by this paper
• Treatment of Acute Ischemic Stroke With the Low-Molecular-Weight Heparin Certoparin: Results of the TOPAS Trial

  2001cited by this paper
• Lubeluzole in Acute Ischemic Stroke Treatment: A Double-Blind Study With an 8-Hour Inclusion Window Comparing a 10-mg Daily Dose of Lubeluzole With Placebo

  2000cited by this paper
• Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study.

  2000cited by this paper
• The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators.

  2000cited by this paper
• Selfotel in acute ischemic stroke : possible neurotoxic effects of an NMDA antagonist.

  2000cited by this paper
• Cervene (Nalmefene) in acute ischemic stroke : final results of a phase III efficacy study. The Cervene Stroke Study Investigators.

  2000cited by this paper
• Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators.

  2000cited by this paper
• Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial. RANTTAS Investigators.

  1998cited by this paper
• Oxford Handbook of Clinical Medicine

  1990cited by this paper
• Oxford Handbook of Clinical Medicine

  1985cited by this paper

• Is NEWS of value for patients with acute stroke?

  2024cites this paper
• Predicting 30-day mortality in intensive care unit patients with ischaemic stroke or intracerebral haemorrhage

  2023cites this paper
• Nurse-led health coaching programme to improve hospital-to-home transitional care for stroke survivors: A randomised controlled trial.

  2021cites this paper
• Serious Adverse Events and Their Impact on Functional Outcome in Acute Ischemic Stroke in the WAKE-UP Trial

  2021cites this paper
• Parkinson's disease and patient related outcomes in stroke: A matched cohort study.

  2020cites this paper
• Safety evaluation of root extract of Pueraria lobata and Scutellaria baicalensis in rats

  2020cites this paper
• Low blood pressure and adverse outcomes in acute stroke: HeadPoST study explanations

  2020cites this paper
• PRECIOUS: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke—statistical analysis plan of a randomised, open, phase III, clinical trial with blinded outcome assessment

  2020cites this paper
• A practical approach to the management of stroke and transient ischemic attack

  2019cites this paper
• PRECIOUS: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke. Rationale and design of a randomised, open, phase III, clinical trial with blinded outcome assessment

  2018cites this paper
• Central adjudication of serious adverse events did not affect trial’s safety results: Data from the Efficacy of Nitric Oxide in Stroke (ENOS) trial

  2018cites this paper
• Results of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2)

  2016cites this paper
• Online Tool to Improve Stratification of Adverse Events in Stroke Clinical Trials

  2016cites this paper
• Regulation and Governance of Multinational Drug Trials in Stroke: Barriers and Possibilities

  2015cites this paper
• Multimorbidity and Patient Safety Incidents in Primary Care: A Systematic Review and Meta-Analysis

  2015cites this paper